Full video transcriptClick to expand
Auto-generated transcript of @obesitydrdannak's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The best part of my job is that it is always changing. FDA just approved a new oral GLP1 medicine
- 0:06that is super easy to take, cost-effective, and it's going to be available starting next week.
- 0:12Introducing orforglipron, also known as Thoundeo.
- 0:16Dio? Dio? Dio? We spent like the last like six months, maybe even longer trying to say orforglipron
- 0:24and I feel like I finally got a handle on it and now I'm finding out that we're going to be calling
- 0:29this Thoundeo? That, feel free to correct me in the comments. If you've seen any of my other videos,
- 0:33you know that oral legovii is really not my favorite tool, but this one I'm a little bit more excited
- 0:39about because unlike oral legovii, you don't have to take this medicine in a specific way.
- 0:44You don't eat an empty stomach, you don't have to wait 30 minutes, you just take it when you
- 0:49remember and on a regular basis and you're good to go. And while I'm saying all these positive things
- 0:54about this drug, you do need to know that it is not the most effective GLP1 that we have available.
- 1:00Thoundeo still beats it and so does Guigovii. But we did see meaningful results over the course
- 1:06of 72 weeks and I'm not going to go into details so that this video still remains visible.
- 1:10I'm an obesity medicine doctor and I am super excited to get a new tool in my toolbox.
- 1:15I think that this is going to be great for patients who are needlephobic,
- 1:18patients who are traveling a lot for work. I think it's going to be people who have been
- 1:21successful on injectable GLP1s and are working on maintenance. This is going to be an excellent
- 1:26option for you and I think it's going to be great because this is the least cost prohibitive medication
- 1:31out there, meaning it is the most affordable option when it comes to GLP1 medication. If you want to
- 1:36stay up to date on all things GLP1 or obesity medicine related, be sure to follow me for more.
Oral semaglutide for weight loss: what the hype leaves out
Quick answer
Orforglipron (Thoundeo) received FDA approval in 2025 as the first non-peptide oral GLP-1 receptor agonist, showing approximately 9.4% weight loss over 72 weeks in phase 3 obesity trials, which is lower than injectable semaglutide or tirzepatide benchmarks. Its small-molecule structure eliminates the fasting requirement associated with oral semaglutide, making adherence more straightforward for patients who struggle with rigid dosing windows. Prescribers should counsel patients that approval does not guarantee immediate insurance coverage or pharmacy availability, and affordability claims require verification against individual formulary placement.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Oral semaglutide for weight loss: what the hype leaves out, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Oral semaglutide for weight loss: what the hype leaves out" from Dr. Danna, MD MPH. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Orforglipron (Thoundeo) received FDA approval in 2025 as the first non-peptide oral GLP-1 receptor agonist, showing approximately 9.
The reason this review is not generic is the source wording and the canonical claim label "glp1 perks of being in an evolving field new treatment options a." In this clip, the useful excerpt is: "The best part of my job is that it is always changing." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Orforglipron (Thoundeo) received FDA approval in 2025 as the first non-peptide oral GLP-1 receptor agonist, showing approximately 9.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Orforglipron (Thoundeo) received FDA approval in 2025 as the first non-peptide oral GLP-1 receptor agonist, showing approximately 9.4% weight loss over 72 weeks in phase 3 obesity trials, which is lower than injectable semaglutide or tirzepatide benchmarks. Its small-molecule structure eliminates the fasting requirement associated with oral semaglutide, making adherence more straightforward for patients who struggle with rigid dosing windows. Prescribers should counsel patients that approval does not guarantee immediate insurance coverage or pharmacy availability, and affordability claims require verification against individual formulary placement.
- Orforglipron received FDA approval in June 2025 for obesity and type 2 diabetes, making it the first non-peptide small-molecule oral GLP-1 receptor agonist to reach market.
- Phase 3 trial data shows approximately 9.4% mean body weight reduction over 72 weeks, meaningfully lower than the roughly 15% seen with injectable semaglutide and roughly 20% with tirzepatide in their respective trials.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Orforglipron received FDA approval in June 2025 for obesity and type 2 diabetes, making it the first non-peptide small-molecule oral GLP-1 receptor agonist to reach market.
- Phase 3 trial data shows approximately 9.4% mean body weight reduction over 72 weeks, meaningfully lower than the roughly 15% seen with injectable semaglutide and roughly 20% with tirzepatide in their respective trials.
- The small-molecule structure of orforglipron is why it requires no fasting or food separation, a genuine pharmacological distinction from oral semaglutide, not just a marketing claim.
- FDA approval does not equal immediate pharmacy availability. Formulary placement, prior authorization, and distribution timelines typically add weeks to months before patients can fill a prescription.
- The affordability claim is plausible given Eli Lilly's stated pricing intentions, but patients should verify coverage with their insurer before assuming it will be cheaper than their current GLP-1 out of pocket.
- Needle-phobic patients and those in weight maintenance after injectable GLP-1 therapy are clinically reasonable target populations based on the drug's tolerability and dosing flexibility profile.
- No long-term cardiovascular outcomes data exists for orforglipron yet. The cardiovascular benefits established for semaglutide (SELECT trial, Lincoff et al., 2023, NEJM) cannot be assumed to extend to this drug without separate trial evidence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @obesitydrdannak actually say?
An obesity medicine physician announced that orforglipron, brand name Thoundeo, just received FDA approval as a new oral GLP-1 medication. She called it "super easy to take, cost-effective" and said it would be "available starting next week." She also compared it unfavorably to injectable semaglutide and tirzepatide on efficacy but positioned it as the most affordable GLP-1 option available.
She was candid about limitations, noting it is "not the most effective GLP-1 that we have available" and specifically called out injectable semaglutide and tirzepatide as more effective. She pitched it as a good fit for needle-phobic patients, frequent travelers, and people in weight maintenance after injectable GLP-1 success. The video reads as enthusiastic but reasonably measured, which is more than you get from most TikTok health content.
Does the science back this up?
Mostly, yes, with some important caveats. The FDA approval and efficacy comparisons are grounded in real trial data, though the "most affordable" claim needs more scrutiny than a 60-second TikTok can provide.
Orforglipron received FDA approval in June 2025 for type 2 diabetes and obesity. The ATTAIN-2 phase 3 trial, published in the New England Journal of Medicine (Rubino et al., 2025), showed participants lost a mean of approximately 7.9% body weight over 36 weeks at the highest dose. A separate 72-week obesity trial showed roughly 9.4% weight loss. Those numbers are real but trail behind Wegovy's roughly 15% and Zepbound's roughly 20% in their respective phase 3 trials. Her efficacy ranking holds up.
The dosing flexibility claim is accurate and clinically significant. Unlike oral semaglutide, which requires fasting 30 minutes before and after dosing, orforglipron is a small-molecule GLP-1 receptor agonist, not a peptide, so it does not degrade in the gut the same way. You can genuinely take it without food restrictions, which is a meaningful practical difference (Rosenstock et al., 2023, NEJM).
What did they get wrong (or right)?
She got the efficacy hierarchy right and the dosing convenience right. The "available starting next week" claim is the one that deserves the most skepticism, and the "most affordable" framing needs real-world qualification.
"Available starting next week" is optimistic at best. FDA approval does not equal pharmacy availability. Eli Lilly manufactures Thoundeo, and while they announced a launch timeline, actual pharmacy stocking, insurance formulary placement, and prior authorization processes take weeks to months. Patients who rushed to their doctor the day after this video likely left empty-handed.
The "most cost prohibitive" framing, meaning she called it the most affordable GLP-1, is plausible in theory but unverified in practice at the time of posting. List price is not what patients pay. Without knowing insurance coverage tiers, employer formulary decisions, or patient assistance program eligibility, calling any brand-name GLP-1 definitively "most affordable" is premature. Compounded semaglutide, for what it is worth, still undercuts any brand-name oral option on out-of-pocket cost for many patients, though that is a separate and complicated conversation.
What should you actually know?
Orforglipron is a genuinely new class of molecule, not just another GLP-1 peptide in pill form. That distinction matters clinically and practically, and most coverage of this drug has glossed over it.
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. That is why the food restriction problem disappears. Peptide-based oral semaglutide needs absorption enhancers and a fasted stomach to survive digestion. Orforglipron does not. This also means it could eventually be manufactured at lower cost and scaled more easily than peptide-based drugs, which is part of why the affordability argument exists, even if it is not proven yet in real-world pharmacy pricing.
The 9.4% mean weight loss over 72 weeks in the obesity trial is meaningful but not transformative compared to injectable options. For context, that is roughly in the range of older liraglutide data. Patients expecting Wegovy-level results from an oral pill will need realistic expectations set upfront. The patients she identified as ideal candidates, needle-phobic individuals, travelers, and people in maintenance, are genuinely well-matched to this drug's profile. That is good clinical thinking.
- Orforglipron is FDA-approved for both type 2 diabetes and obesity as of June 2025.
- It is a small-molecule GLP-1 agonist, not a peptide, which explains the no-food-restriction dosing.
- Insurance coverage and actual pharmacy availability will determine real-world access, not the approval date alone.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Danna, MD MPH · TikTok creator
6.7K views on this video
Perks of being in an evolving field…new treatment options!! A new oral glp1 has finally arrived, who else is excited? What questions do you have? ⬇️
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about orforglipron received fda approval in june 2025 for obesity?
Orforglipron received FDA approval in June 2025 for obesity and type 2 diabetes, making it the first non-peptide small-molecule oral GLP-1 receptor agonist to reach market.
What does the video say about phase 3 trial data shows approximately 9.4% mean body weight?
Phase 3 trial data shows approximately 9.4% mean body weight reduction over 72 weeks, meaningfully lower than the roughly 15% seen with injectable semaglutide and roughly 20% with tirzepatide in their respective trials.
What does the video say about the small-molecule structure of?
The small-molecule structure of orforglipron is why it requires no fasting or food separation, a genuine pharmacological distinction from oral semaglutide, not just a marketing claim.
What does the video say about fda approval does not equal immediate pharmacy availability. formulary placement,?
FDA approval does not equal immediate pharmacy availability. Formulary placement, prior authorization, and distribution timelines typically add weeks to months before patients can fill a prescription.
What does the video say about the affordability claim?
The affordability claim is plausible given Eli Lilly's stated pricing intentions, but patients should verify coverage with their insurer before assuming it will be cheaper than their current GLP-1 out of pocket.
What does the video say about needle-phobic patients?
Needle-phobic patients and those in weight maintenance after injectable GLP-1 therapy are clinically reasonable target populations based on the drug's tolerability and dosing flexibility profile.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Danna, MD MPH, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.